COMP <GO>
GMAB vs RPRX // 10Y YIELD & FRED MACRO BETA
Genmab A/S ADS (NASDAQ) VS. Royalty Pharma plc (Class A) (NASDAQ) • 15-METRIC TALLY: GMAB 7
— RPRX 4
▲ 10Y YIELD & FRED MACRO BETA LEADER: GMAB
LAST: $57.06 (+1.01%) • MKT CAP: $35.61B
macro-sensitivity
1.09
LAST: $67.18 (+1.90%) • MKT CAP: $38.63B
macro-sensitivity
0.94
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GMAB VS. RPRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GMAB | RPRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | 7.00% | +2.90 | GMAB | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.0x | 27.8x | -6.80 | GMAB | /valuation <GO> |
| Free Cash Flow Yield | 2.21% | 6.29% | -4.08 | RPRX | /fcf-yield <GO> |
| Operating Margin | 13.90% | 65.60% | -51.70 | RPRX | /operating-margins <GO> |
| Net Profit Margin | 10.90% | 32.40% | -21.50 | RPRX | /net-margins <GO> |
| Revenue Growth (YoY) | 22.00% | 5.10% | +16.90 | GMAB | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.74 | 2.90 | +0.84 | GMAB | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 85.6 | 72.0 | +13.60 | GMAB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.09 | 0.94 | +0.15 | GMAB | /macro-sensitivity <GO> |
| Forward P/E Multiple | 27.6x | 45.8x | -18.20 | GMAB | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $35.61B | $38.63B | -$3.02B | RPRX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GMAB REV | RPRX REV | GMAB GROSS % | RPRX GROSS % | GMAB FCF | RPRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $2.38B | — | — | — | $2.38B |
| FY 2024 | — | $2.26B | — | — | — | $2.67B |
| FY 2023 | — | $2.35B | — | — | — | $2.88B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GMAB // BETA 1.09
RPRX // BETA 0.94